- Home
- CROX vs CYTK Comparison
CROX vs CYTK Comparison
Compare CROX & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CROX
- CYTK
- Stock Information
- Founded
- CROX 1999
- CYTK 1997
- Country
- CROX United States
- CYTK United States
- Employees
- CROX N/A
- CYTK N/A
- Industry
- CROX Shoe Manufacturing
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- CROX Consumer Discretionary
- CYTK Health Care
- Exchange
- CROX Nasdaq
- CYTK Nasdaq
- Market Cap
- CROX 5.7B
- CYTK 5.6B
- IPO Year
- CROX 2006
- CYTK 2004
- Fundamental
- Price
- CROX $103.80
- CYTK $37.01
- Analyst Decision
- CROX Buy
- CYTK Buy
- Analyst Count
- CROX 13
- CYTK 14
- Target Price
- CROX $128.17
- CYTK $70.92
- AVG Volume (30 Days)
- CROX 1.2M
- CYTK 1.4M
- Earning Date
- CROX 08-07-2025
- CYTK 08-07-2025
- Dividend Yield
- CROX N/A
- CYTK N/A
- EPS Growth
- CROX 26.25
- CYTK N/A
- EPS
- CROX 16.31
- CYTK N/A
- Revenue
- CROX $4,100,808,000.00
- CYTK $19,218,000.00
- Revenue This Year
- CROX $2.95
- CYTK $34.81
- Revenue Next Year
- CROX $2.84
- CYTK $643.79
- P/E Ratio
- CROX $6.36
- CYTK N/A
- Revenue Growth
- CROX 2.09
- CYTK 412.21
- 52 Week Low
- CROX $86.11
- CYTK $29.31
- 52 Week High
- CROX $151.13
- CYTK $61.38
- Technical
- Relative Strength Index (RSI)
- CROX 49.71
- CYTK 65.31
- Support Level
- CROX $103.90
- CYTK $33.07
- Resistance Level
- CROX $107.90
- CYTK $36.99
- Average True Range (ATR)
- CROX 3.30
- CYTK 1.32
- MACD
- CROX 0.43
- CYTK 0.44
- Stochastic Oscillator
- CROX 58.46
- CYTK 99.11
About CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.